Clinical Trial Update: rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) [Phase 3]

View source ↗

Summary

This entry notes the Phase 3 PROST-2 trial evaluating rhPro-UK for acute ischemic stroke within 4.5 hours of onset has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• rhPro-UK (recombinant human pro-urokinase)

Snippet

Sponsor: Tasly Biopharmaceuticals Co., Ltd. | Conditions: Acute Ischemic Stroke | Phase 3 | Status: COMPLETED